Valneva SE Sponsored ADR (NASDAQ:VALN – Get Free Report)’s stock price traded up 1.4% during trading on Monday. The stock traded as high as $5.99 and last traded at $5.82. Approximately 69,379 shares traded hands during mid-day trading, an increase of 184% from the average session volume of 24,393 shares. The stock had previously closed at $5.74.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the company. TD Cowen began coverage on Valneva in a research report on Tuesday, August 11th. They issued a “buy” rating and a $12.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Valneva in a report on Monday, September 14th. One research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Valneva has a consensus rating of “Reduce” and an average price target of $9.30.
Read Our Latest Stock Analysis on Valneva
Valneva Stock Performance
Valneva (NASDAQ:VALN – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.21). Valneva had a negative return on equity of 153.20% and a negative net margin of 110.33%.The firm had revenue of $39.37 million during the quarter, compared to analysts’ expectations of $44.17 million. Equities research analysts anticipate that Valneva SE Sponsored ADR will post -1.27 EPS for the current fiscal year.
Valneva Company Profile
Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France. The company develops, manufactures and commercializes vaccines intended to address infectious diseases with significant unmet medical needs, including travel-related illnesses, endemic diseases and emerging public-health threats.
Valneva’s marketed products include IXIARO, a vaccine for Japanese encephalitis, and DUKORAL, an oral vaccine used for protection against cholera and certain types of traveler’s diarrhea.
Further Reading
- Five stocks we like better than Valneva
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
- Morgan Stanley Is Bullish on Apple—But With a Catch
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
